RTP Mobile Logo

Saturday, September 14, 2019, Houston, Texas, 6:15 AM – 7:45 AM

Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Chronic Lymphocytic Leukemia

An Independent Satellite Symposium During the Society of Hematologic Oncology 2019 Annual Meeting

Event Details

Location
Hilton Americas-Houston
1600 Lamar Street
Houston, Texas 77010
Hotel Phone: (713) 739-8000

Time
5:45 AM – 6:15 AM — Registration
6:15 AM – 7:45 AM — Educational Breakfast Program

Meeting Room
Grand Ballroom G-L (fourth floor)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty:
Faculty to be announced


 

Agenda

For this CME symposium, 4 lymphoma and chronic lymphocytic leukemia (CLL) investigators will serve as the faculty, one of whom will moderate the program. Prior to the event, the invited faculty and several other investigators will complete a survey centered on challenging questions and controversial scenarios specific to the management of CLL. The responses from all experts will be summarized to illustrate the group’s collective perspectives. The program will be divided into 4 modules, each featuring a discussion of select survey results and a faculty member-led review of related clinical research. To make the program more interactive, attendees will use iPads® to complete a survey featuring many of the same questions posed to the investigators, and results from both cohorts will be juxtaposed to highlight any knowledge or practice gaps.

A detailed agenda will be made available in the coming weeks.

CE Information

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Recall the incidence, prognostic significance and clinical implications of select biomarkers and chromosomal abnormalities that may be associated with a diagnosis of CLL, and use this information to develop evidence-based testing algorithms in general oncology practice.
  • Individualize the selection of systemic therapy for patients with newly diagnosed CLL, considering clinical presentation, biomarker profile, coexisting medical conditions and psychosocial status.
  • Evaluate available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with treatment-naïve CLL, and use this information to discern how, if at all, these strategies can be optimally integrated into nonresearch treatment algorithms.
  • Assess the recent FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and determine how to appropriately integrate this regimen into current treatment decision-making.
  • Consider published research data, prior therapeutic exposure and the results of biomarker analyses when developing management strategies for patients with CLL who experience disease progression on first and subsequent lines of therapy.
  • Recognize the biologic rationale for, available research evidence with and ongoing clinical trials evaluating the use of chemotherapy-free combinations involving novel targeted agents in the management of newly diagnosed and progressive CLL, and identify patients who may be suitable candidates for these approaches outside or as part of an ongoing research study.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with current and recently approved systemic therapies in the management of CLL.
  • Recall available and emerging data with other investigational agents, combinations and strategies currently in Phase III testing for CLL, and where applicable, refer eligible patients for trial participation or expanded access programs.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP and Pharmacyclics LLC, an AbbVie Company.

Location

Hilton Americas-Houston
1600 Lamar Street
Houston, Texas 77010
Hotel Phone: (713) 739-8000

Meeting Room
Grand Ballroom G-L (fourth floor)

Directions
Hilton Americas-Houston is the host hotel for the Society of Hematologic Oncology’s seventh annual meeting.

 

Registration

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.